Skip to main content
. Author manuscript; available in PMC: 2024 Jul 5.
Published in final edited form as: N Engl J Med. 2023 Mar 9;388(10):898–912. doi: 10.1056/NEJMoa2210140

Figure 1. Progression-free Survival and Subgroup Analysis.

Figure 1

Panel A shows Kaplan–Meier estimates of progression-free survival. Progression was determined through blinded, independent, central review and included imaging-based progression according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and clinical progression. Panel B shows a forest plot of progression-free survival in prespecified subgroups. FAP denotes familial adenomatous polyposis, NE not estimable, and TKI tyrosine kinase inhibitor.